Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 4Leukemia, Myeloid, Acute 3Ovarian Neoplasms 2Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Leukemia 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinogenesis 1Brain Neoplasms 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × Monatide (IMS 3015) × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡